ASCO Issues New Guidelines for Biomarker Use in Breast Cancer

March 9, 2016
Lisa Schulmeister, MN, RN, ACNS-BC, FAAN

The American Society of Clinical Oncology convened a panel of experts to provide recommendations on appropriate use of breast tumor biomarker assay results to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer.

The American Society of Clinical Oncology (ASCO) convened a panel of experts to provide recommendations on appropriate use of breast tumor biomarker assay results to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer. A literature review of studies published from 2006 through 2014 identified 50 relevant studies.

In addition to estrogen and progesterone receptors and human epidermal growth factor receptor (EGFR) 2, the panel found sufficient evidence of clinical utility for the biomarker assays Oncotype DX, EndoPredict, PAM50, Breast Cancer Index, and urokinase plasminogen activator and plasminogen activator inhibitor type 1 in specific subgroups of breast cancer.

No biomarker except for estrogen receptor, progesterone receptor, and EGFR 2 was found to guide choices of specific treatment regimens. The panel also concluded that treatment decisions should consider disease stage, comorbidities, and patient preferences. The full guidelines can be accessed here.